Differences between ceftriaxone and cefotaxime: Microbiological inconsistencies

Annals of Pharmacotherapy

Volumn 42, Issue 1, 2008, Pages 71-79

  Gums, John G ^a   Boatwright, D Wesston ^b   Camblin, Mark ^c   Halstead, Diane C ^d   Jones, Mark E ^e   Sanderson, Roger ^f  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Medical Affairs   (United States)

^c St Mary's Health System   (United States)

^d PA/Baptist Health   (United States)

^e Eurofins Medinet Inc   (Germany)

^f FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

Cefotaxime; Ceftriaxone; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CEFTRIAXONE; PENICILLIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTICENTER STUDY; NONHUMAN; PATIENT SELECTION; PENICILLIN RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 38049032819     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H620     Document Type: Article

References (34)

1. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
2. CDC. Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae - United States. MMWR Morbid Mortal Wkly Rep 2003;53:152-4.
3. Karlowsky JA, Jones ME, Draghi DC, Sahm DF. Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Antimicrob Agents Chemother 2003;47:3155-60.
4. Thornsberry C, Oglivie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother 1999;43:2612-23.
5. Performance standards for antimicrobial susceptibility testing, 13th informational supplement. NCCLS document M100-S13. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003.
6. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol 2002;40:669-74.
7. Gums JG. Antimicrobial susceptibility trends from 1999-2000: preliminary results of the Antimicrobial Resistance Management (ARM) program. Pharmacotherapy 2001;21:1300-1.
8. Gums JG. Streptococcus pneumoniae susceptibility from 1995-2001: results of the Antimicrobial Resistance Management (ARM) Program. Presented at: Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM, October 20-23, 2002.
9. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
10. Karlowsky JA, Draghi DC, Master RN, Thornsberry C, Jones ME, Sahm DF. Some clinical laboratories in the US report higher susceptibility to ceftriaxone compared to cefotaxime for pneumonia (poster). Presented at: 103rd General Meeting of the American Society of Microbiology, Washington, DC: May 18-22, 2003.
11. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Current Opin Microbiol 2000;3:515-21.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
13. Frimodt-Moller N, Bentzon MW, Thomsen VF. Experimental pneumococcus infection in mice: comparative in vitro and in vivo effect of cefuroxime, cefotaxime and ceftriaxone. Acta Pathol Microbiol Immunol Scand 1987;95:261-7.
14. Dudley MN, Ambrose PG. Monte Carlo PK-PD simulation and new cefotaxime (CTX), ceftriaxone (CRO), and cefepime (FEP) susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin (abstract A-635). Presented at: 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA, September 27-30, 2002.
15. Patel KB, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn Microbiol Infect Dis 1995;22:49-55.
16. Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methyoxyimino cephalosporins. Time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990;26(suppl A):S1-10.
17. Karlowsky JA, Jones ME, Mayfield DC, Thornsberry C, Sahm DF. In vitro evaluation of ceftriaxone activity against recent gram-positive clinical isolates: results from the TSN Database - USA, 1996-2000 (abstract P1299). Clin Microbiol Infect 2001;7(suppl 1):1-394.
18. Baldy LM, Wiersma ST. Surveillance for invasive S. pneumoniae infections in Florida, January 2000-December 2000 (abstract C2-21 07). In: Abstracts of the 41st Conference on Antimicrobial Agents and Chemotherapy, September and December 2001:142.
19. Wisconsin Antibiotic Resistance Network. 2002. Wisconsin Antibiotic Resistance Report. Invasive Streptococcus pneumoniae. www.warnwisconsin.org/surv2002.pdf (accessed 2006 Oct 31).
20. Halstead DC, Gomez N, McCarter YS. Reality of developing a community-wide antibiogram. J Clin Microbiol 2004;42:1-6.
21. Moolenaar RL, Pasley-Shaw R, Harkess JR, Lee A, Crutcher JM. High prevalence of penicillin-nonsusceptible Streptococcus pneumoniae at a community hospital in Oklahoma. Emerg Infect Dis 2000;6:283-9.
22. Gums JG. Update on resistance among respiratory tract infection pathogens: results of the Antimicrobial Resistance Management (ARM) program. Presented at: Annual Meeting of the American College of Chest Physicians, Orlando, FL, October 27-29, 2003.
23. Canton R, Loza E, Morosini MI, Verhoef J, Jones R. Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 1997-2000 (abstract P456). Clin Microbiol Infect 2002;8(suppl 1):75.
24. du Plessis ME, Bingen E, Klugman KP. Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2002;46:2349-57.
25. Smith AM, Klugman KP. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:2393-6.
26. Chiu CH, Su LH, Huang YC, et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan. Antimicrob Agents Chemother 2007;51:3404-6.
27. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999-2005. Pediatr Infect Dis J 2007;26:461-7.
28. Mason EO, Wald ER, Tan TQ, et al. Recurrent systemic pneumococcal disease in children. Pediatr Infect Dis J 2007;26:480-4.
29. McGee L, Jones ME, Boatwright DW, Karlowsky JA, Sahm DF, Klugman KP. Molecular characterization of clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Presented at: 104th General Meeting of the American Society of Microbiology, New Orleans, LA, May 23-27, 2004.
30. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
31. Ferraro MJ, Brown S, Harding I. Prevalence of fluoroquinolone resistance amongst Streptococcus pneumoniae isolates in the United States during the winter of 2000-01 (abstract C20650). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, September 27-30, 2002.
32. Centers for Disease Control and Prevention. Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;53(Feb 27): 152-4.
33. Klepser ME, Klepser DG, Ernst EJ, et al. Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy 2003;23:349-59.
34. Murillo JL, Elysee R. Epidemiology of pneumococcal resistance in an urban hospital setting (presentation S2). Presented at: Annual Conference on Antimicrobial Resistance. Bethesda, MD, June 23-25, 2003.